• Optimized hGBA1 mRNA Restores Lysosomal β-Glucocerebrosidase

  2026-06-11

  This study presents a rationally engineered human GBA1 mRNA platform that significantly enhances β-glucocerebrosidase expression, lysosomal targeting, and enzymatic function in both cellular and animal models of Gaucher disease. The findings highlight the potential of mRNA-LNP therapy to address limitations of traditional enzyme replacement, with implications for translational research in lysosomal storage disorders.

• Ro 3306: Precision CDK1 Inhibition for G2/M Cell Cycle Studi

  2026-06-11

  Ro 3306 empowers researchers to achieve robust, selective G2/M phase arrest and dissect DNA repair mechanisms with high reproducibility. Leveraging the latest insights into mTORC1 oscillations, this guide details advanced workflows and troubleshooting for maximizing Ro 3306's potential in cancer cell synchronization and mechanistic studies.

• One-step TUNEL Cy5 Apoptosis Detection Kit: Mechanism & Evid

  2026-06-10

  The One-step TUNEL Cy5 Apoptosis Detection Kit enables precise detection of DNA fragmentation during apoptosis. This TUNEL assay kit supports reproducible, fluorescence-based quantification in tissue sections and cultured cells. Its robust workflow is validated for programmed cell death research and integrates seamlessly into existing protocols.

• UBE2F-SAG-Driven RHEB Neddylation Amplifies mTORC1 in Liver

  2026-06-10

  This study identifies RHEB as a direct neddylation substrate of the UBE2F-SAG axis, revealing a new mechanism by which mTORC1 activity is enhanced and liver tumorigenesis is promoted. The findings provide mechanistic insight into post-translational regulation of oncogenic signaling and highlight potential therapeutic targets for hepatocellular carcinoma.

• PDI Inhibition Enhances Panobinostat Efficacy in Multiple My

  2026-06-09

  Robinson et al. demonstrate that combining the protein disulfide isomerase (PDI) inhibitor LTI6426 with panobinostat substantially improves anti-myeloma efficacy in preclinical models, enabling dose reduction and minimizing toxicity. This work identifies ER stress pathway effectors as candidate biomarkers and suggests a new avenue for optimizing epigenetic therapy in resistant multiple myeloma.

• Practical Use of 0.4% Trypan Blue Solution for Cell Viabilit

  2026-06-09

  0.4% Trypan Blue Solution provides an established approach for distinguishing live from dead cells in cultured samples, supporting accurate cell viability measurement and cell counting. It should be used for research applications requiring live/dead cell discrimination, but is not appropriate for diagnostic or medical use, nor for quantification of subtle cell death phenotypes.

• Vascular Effects of JAK Inhibitors on Endothelial Inflammati

  2026-06-08

  This study provides a systematic comparison of approved JAK inhibitors, including Tofacitinib citrate, on endothelial cell inflammation and prothrombotic signaling under TNF and IL-17A stimulation. The findings clarify which JAK inhibitors affect cytokine production, adhesion molecule expression, and cytotoxicity, offering valuable insights for immune regulation and cardiovascular research models.

• Stable Lung-Targeted mRNA Delivery via Five-Element Nanopart

  2026-06-08

  This study introduces five-element nanoparticles (FNPs) incorporating poly(β-amino esters) and DOTAP for lung-specific mRNA delivery, offering remarkable stability after lyophilization. The innovation addresses the longstanding challenge of mRNA and nanoparticle instability, extending storage at 4 °C and advancing the feasibility of mRNA-based lung therapies.

• Optimized Sulfonamides for TB: Reduced CYP2C9 Inhibition Ach

  2026-06-07

  This study presents the systematic optimization of sulfaphenazole-derived sulfonamides to enhance antimycobacterial activity against Mycobacterium tuberculosis while minimizing inhibition of CYP 2C9—addressing a key safety concern in TB drug development. The findings inform rational design strategies for safer, more effective sulfonamide-based combination therapies.

• Doxycycline (SKU BA1003): Reliable Solutions for Cell Assays

  2026-06-06

  This article addresses practical laboratory challenges in cell viability, proliferation, and cytotoxicity assays by demonstrating how APExBIO’s Doxycycline (SKU BA1003) enables reproducible, data-driven experiments. Integrating scenario-based Q&A and the latest mechanistic insights, it guides biomedical researchers and lab technicians in optimizing protocols and interpreting results with scientific rigor.

• Annexin V, Human Recombinant: Precision in Immune Cell Apopt

  2026-06-05

  Discover how Annexin V, a leading phosphatidylserine binding protein, empowers advanced apoptosis assays and immune cell research. This article uniquely bridges mechanistic insight with the latest immunological findings, offering researchers practical protocols and critical perspectives.

• Trypsin-Responsive Mesoporous Nanomedicine for Acute Pancrea

  2026-06-05

  This study presents a biomimetic, trypsin-sensitive mesoporous organosilica nanomedicine for acute pancreatitis treatment. By engineering trypsin-cleavable linkers and targeted delivery mechanisms, the researchers achieve precise drug release in injured pancreatic acinar cells, markedly improving therapeutic outcomes in preclinical models.

• Panobinostat Disrupts H2B Ubiquitination in MLL-ALL Therapy

  2026-06-04

  This study demonstrates that panobinostat, a broad-spectrum HDAC inhibitor, exerts potent in vivo anti-leukaemic activity against MLL-rearranged acute lymphoblastic leukaemia by targeting the RNF20/RNF40/WAC-H2B ubiquitination pathway. The findings reveal a mechanistic link between histone deacetylation and ubiquitination that opens new avenues for therapeutic intervention in aggressive infant ALL.

• Live-Dead Cell Staining Kit I: Precision Mammalian Viability

  2026-06-04

  The Live-Dead Cell Staining Kit I (Calcein AM/PI) enables rapid, dual-probe fluorescence discrimination of live and dead mammalian cells. This kit supports robust cell viability and cytotoxicity quantification, critical for translational research and biomaterial evaluation. APExBIO's validated protocol ensures reproducible results in advanced cell membrane integrity assays.

• A40926: Dalbavancin Precursor for Advanced Antibacterial Ass

  2026-06-03

  A40926, the natural glycopeptide and dalbavancin precursor, empowers high-fidelity research against multidrug-resistant Gram-positive pathogens. Discover how its precise mechanism, robust performance metrics, and tunable workflows set a new benchmark for in vitro and in vivo antibacterial assays.

460 records 9/31 page Previous Next First page 上5页 678910 下5页 Last page